Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data
# Background While the prognosis is generally good for hormone receptor–positive (HR+), human epidermal growth factor–negative (HER2–) early breast cancer (EBC) patients, up to 30% of patients with high-risk clinical and/or pathologic features experience recurrence. # Objectives This retrospective...
Saved in:
| Main Authors: | Heidi Loponen, Juha Mehtälä, Laila Mehkri, Astrid Torstensson, Anna Emde, Tero Ylisaukko-oja, Walid Fakhouri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2025-06-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.137277 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-World Observational Study of Incidence and Outcomes in an HR+/HER2– Early Breast Cancer Population with High-Risk of Recurrence in Finland
by: Ravinder Singh, et al.
Published: (2025-02-01) -
The association between body mass index groups and metabolic comorbidities with healthcare and medication costs: a nationwide biobank and registry study in Finland
by: Aino Vesikansa, et al.
Published: (2023-12-01) -
Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study
by: Judy King, et al.
Published: (2025-07-01) -
Survival outcomes for HER2-low breast cancer: Danish national data
by: Michael Sode, et al.
Published: (2024-11-01) -
Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer
by: Karam Aboud, et al.
Published: (2025-07-01)